DBVT DBV Technologies S.A.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1613780 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-31.5%
TTM net income YoY-65.6%
TTM EPS YoY42.3%
Revenue 3-yr CAGR-11.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-5,418.8%
Net margin-5,392.2%
FCF margin-4,986.9%
EBITDA margin—
Returns
ROE-205.8%
ROA-127.2%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets31.0%
Debt / equity0.00x
Current ratio3.24x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.91x
Accruals ratio-11.6%
Payout ratio—
Capex / revenue87.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $5.64M | $4.15M | $15.73M | $4.84M | $5.71M |
| R&D expense | $116.68M | $89.34M | $60.22M | $75.54M | $70.34M |
| SG&A expense | $32.79M | $28.74M | $29.50M | $24.32M | $30.52M |
| Operating income | -$147.06M | -$116.59M | -$76.43M | -$96.63M | -$98.61M |
| Pretax income | -$146.46M | -$113.86M | -$72.72M | -$96.20M | -$98.19M |
| Income tax | $491,000 | $55,000 | $7,000 | $70,000 | -$381,000 |
| Net income | -$146.95M | -$113.92M | $72.71M | $96.27M | -$97.81M |
| EBITDA | -$144.07M | -$113.87M | -$72.87M | -$93.93M | -$94.21M |
| EPS (basic) | -1.05 | -1.17 | -0.76 | -1.24 | -1.78 |
| EPS (diluted) | -1.05 | -1.17 | -0.76 | -1.24 | -1.78 |
| Weighted avg. shares (diluted) | 139.57M | 97.00M | 95.12M | 77.38M | 54.92M |
| Balance sheet | |||||
| Cash & equivalents | $194.20M | $32.50M | $141.37M | $209.19M | $77.30M |
| Receivables | — | — | $0 | $0 | $0 |
| Current assets | $212.90M | $44.39M | $158.91M | $223.07M | $114.39M |
| PP&E, net | $10.40M | $11.31M | $12.62M | $15.10M | $18.15M |
| Intangibles | $0 | $40,000 | $58,000 | $10,000 | $22,000 |
| Total assets | $233.70M | $65.66M | $182.99M | $246.52M | $146.72M |
| Current liabilities | $58.00M | $31.14M | $37.34M | $29.52M | $31.40M |
| Long-term debt | $0 | — | — | — | $510,000 |
| Total debt | $0 | — | — | — | $510,000 |
| Total liabilities | $64.90M | $38.27M | $42.80M | $52.06M | $47.45M |
| Shareholders' equity | $168.80M | $27.40M | $140.19M | $194.45M | $99.27M |
| Net debt | -$194.20M | — | — | — | -$76.79M |
| Shares outstanding | — | 102.85M | — | — | — |
| Cash flow statement | |||||
| Operating cash flow | -$121.18M | -$104.47M | -$79.65M | -$55.67M | -$108.24M |
| Capital expenditure | $532,000 | $2.34M | $677,000 | $754,000 | $910,000 |
| Free cash flow | -$121.71M | -$106.81M | -$80.33M | -$56.42M | -$109.15M |
| Investing cash flow | -$1.37M | -$757,000 | -$808,000 | -$100,000 | -$433,000 |
| Financing cash flow | $276.18M | $587,000 | $6.77M | $194.12M | $274,000 |
| Depreciation & amortization | $2.99M | $2.72M | $3.57M | $2.70M | $4.40M |
| Stock-based compensation | $5.39M | $4.62M | $6.02M | $5.03M | $3.12M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.